Ref ID: 18785
Author:
R. E. Lewis, Pharm.D. – Professor1, F. Sampsonas, M.D. – Researcher 2, S. Georgiadou, M.D. – Fellow 2, G. Chamilos, M.D. – Fellow 3, D. P. Kontoyiannis, M.D. – Professor 2;
Author address:
1Univ. of Houston Coll. of Pharmacy, Houston, TX, 2The Univ. of Texas M.D. Anderson Cancer Ctr., Houston, TX, 3Univ. of Texas M.D. Anderson Cancer Ctr., Houston, TX.
Full conference title:
52nd Annual ICAAC
Date: 9 September 2014
Abstract:
Background: Pulmonary mucormycosis (PM) is a severe opportunistic mycosis that has variable clinical history and few prognostic markers for outcome assessment in hematology patients. Methods:Thirteen clinical risk factors encompassing immunosuppression (e.g., neutropenia, lymphocytopenia, steroids, etc.), metabolic derangement (hyperglycemia, acidosis, iron overload, etc.) and severity of clinical presentation (e.g, # pulm. nodules, dissemination, etc.) present at the diagnosis of PM (proven or probable, EORTC/MSG criteria) were screened for association with mortality by univariate analysis in 75 consecutive hematology patients from 2000-2011. Significant variables (P<0.05) were entered into a multivariate Cox-proportional hazard regression model to identify independent risk factors for patient mortality at 28 days. Results:When adjusted for time of initiation of a Mucorales-active antifungal, the probability of mortality at 28d was 3 or 4x higher in patients with a baseline ALC of 100-500 or < 100 vs. patients with an ALC greater than 500. A baseline ALC < 100 was more common in patients with uncontrolled malignancy and allogeneic HSCT (P=0.015), but was not exclusive to these populations. Conclusions: Severe lymphocytopenia at PM diagnosis is an important predictor of early death in hematology patients. Future clinical studies should consider ALC as a surrogate marker for severe immunosuppression and outcome stratification.
Abstract Number: M-1679
Conference Poster: y
Conference Year: 2012
Link to conference website: NULL
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Teclegiorgis Gebremariam [MS]1, Yiyou Gu [PhD]1, Sondus Alkhazraji [PhD]1, Jousha Quran1, Laura K. Najvar [BS]2, Nathan P. Wiederhold [PharmD]2, Thomas F. Patterson [MD]2, Scott G. Filler [MD]1,3, David A. Angulo (MD)4, Ashraf S. Ibrahim [PhD]1,3*,
2024
91
n/a
-
v
Ruta Petraitiene (US)
2024
90
n/a
-
v
Fabio Palmieri (CH), Junier Pilar
2024
89
n/a
-
v
Evelyne Côté (CA)
2024
88
n/a
-
v
Eliane Vanhoffelen (BE)
2024
87
n/a
-
v
Teclegiorgis Gebremariam, Yiyou Gu, Eman Youssef, Sondus Alkhazraji, Joshua Quran, Nathan P. Wiederhold, Ashraf S. Ibrahim
2024
86
n/a
-
v
Thomas Orasch (DE)
2024
85
n/a
-
v
Julien Alex, Katherine González, Gauri Gangapurwala, Antje Vollrath, Zoltán Cseresnyés, Christine Weber, Justyna A. Czaplewska, Stephanie Hoeppener, Carl-Magnus Svensson, Thomas Orasch, Thorsten Heinekamp, Carlos Guerrero-Sánchez, Marc Thilo Figge, Ulrich S. Schubert, Axel A. Brakhage
2024
84
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
83
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
82
n/a